Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Current Colorectal Cancer Reports
Published in: Current Colorectal Cancer Reports 3/2017

01-06-2017 | Surgery and Surgical Innovations in Colorectal Cancer (S Huerta, Section Editor)

Current Views on the Interval Between Neoadjuvant Chemoradiation and Surgery for Rectal Cancer

Authors: Maria Emilia Carvalho e Carvalho, Bruno Augusto Alves-Martins, Luiz Felipe de Campos-Lobato

Published in: Current Colorectal Cancer Reports | Issue 3/2017

Login to get access

Abstract

Neoadjuvant chemoradiation (CRT) has been established as standard treatment for stage II and III rectal cancer, and delayed interval between CRT and rectal resection has emerged as appropriate treatment due to the marked benefits associated with this approach. Despite favorable findings on downstaging and pathological complete response without increasing in morbidity and mortality, no significant improvement in sphincter preservation rate and rectal cancer overall survival has been observed with the current recommended 6–8-week interval. Trials are currently underway and may provide answers regarding the optimal interval between CRT and surgical resection, but until now, the best interval between CRT and surgery remains unclear.
Literature
1.
2.
Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.CrossRefPubMed
3.
Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol. 1999;17:2396.CrossRefPubMed
4.
5.
Wong RK, Tandan V, De Silva S, Figueredo A. Pre-operative CRT-surgery interval in rectal cancer radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev. 2007;2:CD002102.
6.
7.
• Foster JD, Jones EL, Falk S, Cooper EJ, Francis NK. Timing of surgery after long-course neoadjuvant chemoradiotherapy for rectal cancer: a systematic review of the literature. Dis Colon Rectum. 2013;56:921–30. doi:10.​1097/​DCR.​0b013e31828aedcb​. In this systematic review of 16 studies, 9 of them reported anastomotic complications, but no difference between intervals was observed as shown in subsequent studies
8.
• Hu MH, Huang RK, Zhao RS, Yang KL, Wang H. Does neoadjuvant therapy increase the incidence of anastomotic leakage after anterior resection for mid and low rectal cancer? A systematic review and meta-analysis. Color Dis. 2016; doi:10.​1111/​codi.​13424. A meta-analysis demontrating that CRT and interval to surgery were not associated to increased postoperative anastomotic leak
9.
Moore HG, et al. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon rectum. 2004;47(3):279–86.
10.
•• Petrelli F, Sgroi G, Sarti E, Barni S. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies. Ann Surg. 2016;263(3):458–64. A meta-analysis of 13 prospective and retrospective studies demonstrating an increase by 6% in pCR with longer intervals between CRT and surgery (more than 6–8 weeks) with no difference in outcomes and complication rates CrossRefPubMed
11.
•• Lefevre JH, Mineur L, Kotti S, Rullier E, Rouanet P, de Chaisemartin C, Meunier B, Mehrdad J, Cotte E, Desrame J, Karoui M, Benoist S, Kirzin S, Berger A, Panis Y, Piessen G, Saudemont A, Prudhomme M, Peschaud F, Dubois A, Loriau J, Tuech JJ, Meurette G, Lupinacci R, Goasgen N, Parc Y, Simon T, Tiret E. Effect of interval (7 or 11 weeks) between neoadjuvant Radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol. 2016;34:3773. The first randomized trial that demonstrated no impact on pCR waiting longer interval alone (11 weeks after CRT) and a higher morbidity and technically more difficult surgical procedure associated with this approach CrossRef
12.
•• Huntington CR, Boselli D, Symanowski J, Hill JS, Crimaldi A, Salo JC. Optimal timing of surgical resection after radiation in locally advanced rectal adenocarcinoma: an analysis of the National Cancer Database. Ann Surg Oncol. 2016;23(3):877–87. doi:10.​1245/​s10434-015-4927-z. A retrospective study evaluating 6937 patients from the National Cancer Database demonstrating that intervals longer than 60 days should be done with caution due to increased rate of positive surgical margins and decreased survival and sphincter preservation CrossRefPubMed
13.
de Campos-Lobato LF, et al. Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence. Ann Surg Oncol. 2011;18(6):1590–8.CrossRefPubMed
14.
de Campos-Lobato LF, Geisler DP, Moreira ADL, Stocchi L, Dietz D, Kalady MF. Neoadjuvant therapy for rectal cancer: the impact of longer interval between chemoradiation and surgery. J Gastrointest Surg. 2011;15(3):444–50.CrossRefPubMed
15.
Kalady MF, et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg. 2009;250(4):582–9.PubMed
16.
de Campos-Lobato LF, et al. Downstaging without complete pathologic response after neoadjuvant treatment improves cancer outcomes for cIII but not cII rectal cancers. Ann Surg Oncol. 2010;17(7):1758–66.CrossRefPubMed
17.
Habr-Gama A, Gama-Rodrigues J, Julião GPS, Proscurshim I, Sabbagh C, Lynn PB, et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Bio Phys. 2014;88:822–8.CrossRef
18.
• Cotte E, et al. Pathologic response, when increased by longer interval, is a marker but not the cause of good prognosis in rectal cancer: 17-year follow-up of the Lyon R90-01 randomized trial. International Journal of Radiation Oncology Biology Physics. 2016;94(3):544–53. The follow-up of the Lyon trial demonstrated that after 17 years, despite the impact on pCR with longer interval, no difference was observed in survival CrossRef
19.
Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29(35):4633–40.CrossRefPubMed
20.
Denost Q, Adam JP, Rullier A, Buscail E, Laurent C, Rullier E. Perineal transanal approach: a new standard for laparoscopic sphincter-saving resection in low rectal cancer, a randomized trial. Ann Surg. 2014;260(6):993–9.CrossRefPubMed
21.
Verseveld M, de Graaf EJ, Verhoef C, et al. Chemoradiation therapy for rectal cancer in the distal rectum followed by organsparing transanal endoscopic microsurgery (CARTS study). Br J Surg. 2015;102(7):853–60.CrossRefPubMed
22.
Morino M, Risio M, Bach S, et al. Early rectal cancer: the European Association for Endoscopic Surgery (EAES) clinical consensus conference. Surg Endosc. 2015;29(4):755–73.CrossRefPubMed
23.
Pucciarelli S, De Paoli A, Guerrieri M, et al. Local excision after preoperative chemoradiotherapy for rectal cancer: results of a multicenter phase II clinical trial. Dis Colon rectum. 2013;56(12):1349–56.
24.
Garcia-Aguilar J, Shi Q, Thomas Jr CR, et al. A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. Ann Surg Oncol. 2012;19(2):384–91.CrossRefPubMed
25.
Garcia-Aguilar J, Renfro LA, Chow OS, et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol. 2015;16(15):1537–46.CrossRefPubMedPubMedCentral
26.
Stipa F, Picchio M, Burza A, Soricelli E, Vitelli CE. Long-term outcome of local excision after preoperative chemoradiation for ypT0 rectal cancer. Dis Colon rectum. 2014;57(11):1245–52.
27.
Monson JRT, et al. Practice parameters for the management of rectal cancer (revised). Dis Colon rectum. 2013;56(5):535–50.
28.
Beck DE, et al. The ASCRS manual of colon and rectal surgery. New York: Springer; 2014.CrossRef
29.
Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835–44.CrossRefPubMed
30.
Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99:918–28.CrossRefPubMed
31.
Zorcolo L, Rosman AS, Restivo A, et al. Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a metaanalysis. Ann Surg Oncol. 2012;19:2822–32.CrossRefPubMed
32.
Wang XJ, Zheng ZR, Chi P, Lin HM, Lu XR, Huang Y. Effect of interval between neoadjuvant chemoradiotherapy and surgery on oncological outcome for rectal cancer: a systematic review and meta-analysis. Gastroenterol Res Pract. 2016;2016:6756859.PubMedPubMedCentral
33.
Garcia-Aguilar J, Smith DD, Avila K, et al. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg. 2011;254(1):97–102.CrossRefPubMedPubMedCentral
34.
Huerta S. Interval between neoadjuvant chemoradiation and surgery for the management of rectal cancer. J Gastrointest Surg. 2011;15(7):1292.CrossRefPubMed
35.
Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Color Dis. 1997;12(1):19–23.CrossRef
36.
Bujko K, et al. Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: an analysis of outcomes in a randomized trial. Int J Radiat Oncol Biol Phys. 2007;67(2):369–77.CrossRefPubMed
37.
Chan AKP, et al. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61(3):665–77.CrossRefPubMed
38.
Quah H-M, et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer. 2008;113(1):57–64.CrossRefPubMed
39.
Stipa F, et al. A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography. Ann Surg Oncol. 2006;13(8):1047–53.CrossRefPubMed
40.
Meade PG, et al. Preoperative chemoradiation downstages locally advanced ultrasound-staged rectal cancer. Am J Surg. 1995;170(6):609–13.CrossRefPubMed
41.
Kim J-S, et al. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2002;54(2):403–8.CrossRefPubMed
42.
Guillem JG, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 2005;241(5):829–38.CrossRefPubMedPubMedCentral
43.
Bosset J-F, et al. Preoperative radiochemotherapy in rectal cancer: long-term results of a phase II trial. Int J Radiat Oncol Biol Phys. 2000;46(2):323–7.CrossRefPubMed
44.
Mehta VK, et al. Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 to T4 rectal cancer. Dis Colon rectum. 2001;44(1):52–8.
45.
Bujko K, et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol. 2004;72(1):15–24.CrossRefPubMed
46.
47.
Glehen O, Chapet O, Adham M, Nemoz JC, Gerard JP. Lyons Oncology Group. Long-term results of the Lyons R90-01 randomized trial of preoperative radiotherapy with delayed surgery and its effect on sphincter-saving surgery in rectal cancer. Br J Surg. 2003;90:996–8.CrossRefPubMed
48.
Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–33.CrossRefPubMed
49.
Kapiteijn E, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638–46.CrossRefPubMed
50.
Heald RJ, Ryall RDH. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;327(8496):1479–82.CrossRef
51.
Wibe A, et al. A national strategic change in treatment policy for rectal cancer—implementation of total mesorectal excision as routine treatment in Norway. A national audit. Dis Colon rectum. 2002;45(7):857–66.
52.
Carlsen E, et al. Effect of the introduction of total mesorectal excision for the treatment of rectal cancer. Br J Surg. 1998;85(4):526–9.CrossRefPubMed
53.
Schlichting E, Carlsen E. Introduction of a new surgical technique in rectal cancer. Tidsskrift for den Norske laegeforening: tidsskrift for praktisk medicin, ny raekke. 1998;118(12):1846–9.
54.
Wiig MD, et al. Mesorectal excision for rectal cancer: a view from Europe. Semin Surg Oncol. 1998;15(2):78.CrossRefPubMed
55.
Collette L, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol. 2007;25(28):4379–86.CrossRefPubMed
56.
Krook JE, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324(11):709–15.CrossRefPubMed
57.
Steele Jr G. Adjuvant therapy for patients with colon and rectal cancer: clinical indications for multimodality therapy in high-risk groups and specific surgical questions for future multimodality trials. Surgery. 1992;112(5):847.PubMed
58.
• Zeng WG, Zhou ZX, Liang JW, Wang Z, Hou HR, Zhou HT, Zhang XM, Hu JJ. Impact of interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer on surgical and oncologic outcome. J Surg Oncol. 2014;110(4):463–7. doi:10.​1002/​jso.​23665. This retrospective study analyzed 255 patients and demonstrated, in addition to higher pCR and CRM rate, a decreased 3-year local recurrence in the longer interval group CrossRefPubMed
59.
Habr-Gama A, et al. Consolidation chemotherapy during neoadjuvant chemoradiation (CRT) for distal rectal cancer leads to sustained decrease in tumor metabolism when compared to standard CRT regimen. Radiat Oncol. 2016;11(1):24.CrossRefPubMedPubMedCentral
60.
•• Garcia-Aguilar J, Chow OS, Smith DD, Marcet JE, Cataldo PA, Varma MG, Kumar AS, Oommen S, Coutsoftides T, Hunt SR, Stamos MJ, Ternent CA, Herzig DO, Fichera A, Polite BN, Dietz DW, Patil S, Avila K. Timing of rectal cancer response to chemoradiation consortium. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16(8):957–66. doi:10.​1016/​S1470-2045(15)00004-2. This phase 2 trial analyzed 259 patients from 17 institutions regarding association between interval and pCR. As a strategy to avoid recurrence, a different number of chemotherapy cycles were given to patients during the interval allowing longer intervals. A positive association between longer intervals and pCR was observed CrossRefPubMedPubMedCentral
Metadata
Title
Current Views on the Interval Between Neoadjuvant Chemoradiation and Surgery for Rectal Cancer
Authors
Maria Emilia Carvalho e Carvalho
Bruno Augusto Alves-Martins
Luiz Felipe de Campos-Lobato
Publication date
01-06-2017
Publisher
Springer US
Published in
Current Colorectal Cancer Reports / Issue 3/2017
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-017-0370-9

Other articles of this Issue 3/2017

Current Colorectal Cancer Reports 3/2017 Go to the issue

Genetic Syndromes, Screening, and Surveillance in Colorectal Cancer (N Kubiliun, Section Editor)

Personalizing Colon Cancer Screening: Role of Age and Comorbid Conditions

Genetic Syndromes, Screening, and Surveillance in Colorectal Cancer (N Kubiliun, Section Editor)

DNA Mismatch Repair and Lynch Syndrome

Systemic Therapies in Colorectal Cancer (RD Kim, Section Editor)

Anti-EGFR and Anti-VEGF Agents in First-Line Therapy for Advanced Colorectal Cancer

Personalized Medicine in Colorectal Cancer (D Cunningham and EC Smyth, Section Editors)

Personalizing Maintenance Therapy in Metastatic Colorectal Cancer

Surgery and Surgical Innovations in Colorectal Cancer (S Huerta, Section Editor)

Current Trends in the Use of Bowel Preparation for Colorectal Surgery

Radiation Therapy and Radiation Therapy Innovations in Colorectal Cancer (JY Wo, Section Editor)

Radiotherapy for the Primary Tumor in Patients with Metastatic Rectal Cancer

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits